AU2012258485A1 - Chromatographic methods - Google Patents
Chromatographic methods Download PDFInfo
- Publication number
- AU2012258485A1 AU2012258485A1 AU2012258485A AU2012258485A AU2012258485A1 AU 2012258485 A1 AU2012258485 A1 AU 2012258485A1 AU 2012258485 A AU2012258485 A AU 2012258485A AU 2012258485 A AU2012258485 A AU 2012258485A AU 2012258485 A1 AU2012258485 A1 AU 2012258485A1
- Authority
- AU
- Australia
- Prior art keywords
- column
- cation exchange
- exchange chromatography
- erythropoietin
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004587 chromatography analysis Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 67
- 238000005277 cation exchange chromatography Methods 0.000 claims abstract description 63
- 238000011069 regeneration method Methods 0.000 claims abstract description 16
- 230000008929 regeneration Effects 0.000 claims abstract description 14
- 102000003951 Erythropoietin Human genes 0.000 claims description 79
- 108090000394 Erythropoietin Proteins 0.000 claims description 79
- 229940105423 erythropoietin Drugs 0.000 claims description 73
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 73
- 239000000243 solution Substances 0.000 claims description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 238000010828 elution Methods 0.000 claims description 39
- 239000000872 buffer Substances 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 34
- 238000005341 cation exchange Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000008213 purified water Substances 0.000 claims description 28
- 238000011010 flushing procedure Methods 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- -1 sulfopropyl Chemical group 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 108010048732 pegylated erythropoietin Proteins 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- 230000001172 regenerating effect Effects 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 7
- 239000008366 buffered solution Substances 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 5
- 102000044890 human EPO Human genes 0.000 claims description 5
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 238000012437 strong cation exchange chromatography Methods 0.000 claims 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 description 56
- 235000002639 sodium chloride Nutrition 0.000 description 44
- 239000000126 substance Substances 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000005526 G1 to G0 transition Effects 0.000 description 17
- 238000000746 purification Methods 0.000 description 15
- 230000006320 pegylation Effects 0.000 description 14
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 239000008057 potassium phosphate buffer Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229910000160 potassium phosphate Inorganic materials 0.000 description 6
- 235000011009 potassium phosphates Nutrition 0.000 description 6
- 238000011210 chromatographic step Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 4
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003729 cation exchange resin Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000012928 buffer substance Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000003518 caustics Substances 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001415846 Procellariidae Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012799 strong cation exchange Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000012607 strong cation exchange resin Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000012610 weak anion exchange resin Substances 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
- 239000012608 weak cation exchange resin Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Abstract
CHROMATOGRAPHIC METHODS The current invention comprises a method for the regeneration of a cation exchange chromatography column.
Description
S&F Ref: 936427D1 AUSTRALIA PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT Name and Address F. Hoffmann-La Roche AG, of Grenzacherstrasse 124, of Applicant: CH-4070, Basel, Switzerland Actual Inventor(s): Axel Schroth Axel Wessner Klaus Reichert Josef Burg Hartmut Schurig Address for Service: Spruson & Ferguson St Martins Tower Level 35 31 Market Street Sydney NSW 2000 (CCN 3710000177) Invention Title: Chromatographic methods The following statement is a full description of this invention, including the best method of performing it known to me/us: 5845c(6915651_1) - 1 24383 WO-ASK Chromatographic methods The current invention is in the field of chromatographic separation methods useful for the purification of polypeptides, especially of PEGylated polypeptides. Background of the Invention Proteins play an important role in today's medical portfolio. For human 5 application every therapeutic protein has to meet distinct criteria. To ensure the safety of biopharmaceutical agents to humans by-products accumulating during the production process have to be removed especially. To fulfill the regulatory specifications one or more purification steps have to follow the manufacturing process. Among other things, purity, throughput, and yield play an important role 10 in determining an appropriate purification process. Different methods are well established and widespread used for protein purification, such as affinity chromatography with microbial proteins (e.g. protein A or protein G affinity chromatography), ion exchange chromatography (e.g. cation exchange (sulfopropyl or carboxymethyl resins), anion exchange (amino 15 ethyl resins) and mixed-mode ion exchange), thiophilic adsorption (e.g. with beta mercaptoethanol and other SH ligands), hydrophobic interaction or aromatic adsorption chromatography (e.g. with phenyl-sepharose, aza-arenophilic resins, or m-aminophenylboronic acid), metal chelate affinity chromatography (e.g. with Ni(Il)- and Cu(Il)-affinity material), size exclusion chromatography, and 20 electrophoretical methods (such as gel electrophoresis, capillary electrophoresis) (Vijayalakshmi, M.A., Appl. Biochem. Biotech. 75 (1998) 93-102). Conjugations are reported, for example, for polyethylene glycol (PEG) and Interleukin-6 (EP 0 442 724), for PEG and erythropoietin (WO 01/02017), for chimeric molecules comprising Endostatin and immunoglobulins 25 (US 2005/008649), for secreted antibody based fusion proteins (US 2002/147311), for fusion polypeptides comprising albumin (US 2005/0100991; human serum albumin US 5,876,969), for PEGylated polypeptides (US 2005/0114037), and for interferon fusions. Necina, R., et al. (Biotechnol. Bioeng. 60 (1998) 689-698) reported the capture of 30 human monoclonal antibodies directly from cell culture supernatants by ion -2 exchange media exhibiting high charge density. In WO 89/05157 a method is reported for the purification of product immunoglobulins by directly subjecting the cell culture medium to a cation exchange treatment. A one-step purification of monoclonal IgG antibodies from mouse ascites is described by Danielsson, A., et al., 5 J. Immun. Meth. 115 (1988), 79-88. A method for purifying a polypeptide by ion exchange chromatography is reported in WO 2004/024866 in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants. In EP 0 530 447 a process for purifying IgG monoclonal antibodies by a combination of three chromatographic steps is reported. A facile purification of mono 10 PEGylated interleukin-1 receptor antagonist is reported by Yu, G., et al., in Process Biotechnol. 42 (2007) 971-977. Wang et al. (Wang, H., et al., Peptides 26 (2005) 1213-1218) reports the purification of hTFF3 expressed in E.coli by a two step cation exchange chromatography. Yun et al. (Yun, Q., et al., J. Biotechnol. 118 (2005) 67-74) report the purification of PEGylated rhG-CSF by two consecutive 15 ion-exchange chromatography steps. Summary of the Invention One aspect of the current invention is a method for the regeneration of a cation exchange chromatography column after the elution of compounds of interest comprising the following steps in this order: 20 - eluting adsorbed polypeptides from the column with an aqueous buffered solution comprising sodium chloride at a concentration of at least 500 mM, - flushing the column with purified water, - applying a 0.5 M sodium hydroxide solution to the column, - flushing the column with purified water, 25 - applying a solution comprising 0.5 M sodium dihydrogen phosphate and 1 M phosphoric acid to the column, - flushing the column with purified water, - applying a 0.5 M sodium hydroxide solution to the column for at least 4 hours, and -3 - regenerating the cation exchange column by flushing the column with purified water. Detailed Description of the Invention The current invention comprises as first aspect a method for the regeneration of a 5 cation exchange chromatography column after the elution of compounds of interest comprising the following steps: - removing residual bound polypeptides from the cation exchange column with a aqueous buffered solution comprising sodium chloride, - flushing the column with purified water, 10 - applying a sodium hydroxide solution to the column, - flushing the column with purified water, - applying a solution comprising sodium dihydrogen phosphate and phosphoric acid to the column, - flushing the column with purified water, 15 - applying a 0.5 M sodium hydroxide solution to the column for at least 4 hours, and - regenerating the cation exchange column by flushing the column with purified water. The term "purified water" as used within this application denotes water for 20 injection according to US Pharmacopeia. The term "ion exchange material" as used within this application denotes an immobile high molecular weight matrix that carries covalently bound charged substituents used as stationary phase in ion exchange chromatography. For overall charge neutrality not covalently bound counter ions are bound thereto. The "ion 25 exchange material" has the ability to exchange its not covalently bound counter ions for similarly charged ions of the surrounding solution. Depending on the charge of its exchangeable counter ions the "ion exchange resin" is referred to as cation exchange resin or as anion exchange resin. Depending on the nature of the charged group (substituent) the "ion exchange resin" is referred to as, e.g. in the -4 case of cation exchange resins, sulfonic acid resin (S), or sulfopropyl resin (SP), or carboxymethyl resin (CM). Depending on the chemical nature of the charged group/substituent the "ion exchange resin" can additionally be classified as strong or weak ion exchange resin, depending on the strength of the covalently bound 5 charged substituent. For example, strong cation exchange resins have a sulfonic acid group, preferably a sulfopropyl group, as charged substituent, weak cation exchange resins have a carboxylic group, preferably a carboxymethyl group, as charged substituent, and weak anion exchange resins have a diethylaminoethyl group as charged substituent. In one embodiment the cation exchange chromatography 10 column contains a sulfopropyl cation exchange resin, i.e. it is a sulfopropyl cation exchange chromatography column. Different types of ion exchange materials, i.e. stationary phases, are available under different names and from a multitude of companies such as e.g. cation exchange materials Bio-Rexc (e.g. type 70), ChelexO (e.g. type 100), Macro-Prepe (e.g. type 15 CM, High S, 25 S), AGO (e.g. type 50W, MP) all available from BioRad Laboratories, WCX 2 available from Ciphergen, DowexD MAC-3 available from Dow chemical company, Mustang C and Mustang S available from Pall Corporation, Cellulose CM (e.g. type 23, 52), hyper-D, partisphere available from Whatman plc., Amberlite@ IRC (e.g. type 76, 747, 748), Amberlites GT 73, 20 Toyopearlm (e.g. type SP, CM, 650M) all available from Tosoh Bioscience GmbH, CM 1500 and CM 3000 available from BioChrom Labs, SP-SepharoseTM, CM SepharoseTM available from GE Healthcare, Poros resins available from PerSeptive Biosystems, Asahipak ES (e.g. type 502C), CXpak P, IEC CM (e.g. type 825, 2825, 5025, LG), lEC SP (e.g. type 420N, 825), IEC QA (e.g. type LG, 825) available from 25 Shoko America Inc., 50W cation exchange resin available from Eichrom Technologies Inc. In one embodiment the cation exchange material is a strong cation exchange material such as Macro-PrepO High S or 25S, or MacroCap SP, or ToyopearlO SP 650M, or Source S, or SP Sepharose, or POLYCAT A. Exemplary anion exchange materials are Dowex@ 1 available from Dow chemical company, 30 AG@ (e.g. type 1, 2, 4), Bio-Rex& 5, DEAE Bio-Gel 1, Macro-Prep@ DEAE all available from BioRad Laboratories, anion exchange resin type I available from Eichrom Technologies Inc., Source Q, ANX Sepharose 4, DEAE Sepharose (e.g. type CL-6B, FF), Q Sepharose, Capto Q, Capto S all available from GE Healthcare, AX-300 available from PerkinElmer, Asahipak ES-502C, AXpak WA (e.g. type 624, 35 G), IEC DEAE all available from Shoko America Inc., Amberlites IRA-96, -5 ToyopearlO DEAE, TSKgel DEAE all available from Tosoh Bioscience GmbH, Mustang Q available from Pall Corporation. The term "flushing" as used within this application denotes the washing of a column with two or more column volumes of a specified solution. 5 The term "same type of cation exchange material" denotes two consecutive ion exchange chromatography steps which are performed by employing an identical cation exchange material. This means that the consecutive cation exchange chromatography steps are carried out by using either a first portion of the cation exchange material for the first cation exchange chromatography step and by using 10 the second portion of the same cation exchange material for the second cation exchange chromatography or by using the same cation exchange material for both cation exchange chromatography steps. The terms "step elution" and "step elution method", which are used interchangeably within this application, denote a method wherein e.g. the 15 concentration of a substance causing elution, i.e. the dissolution of a bound compound from a material, is raised or lowered at once, i.e. directly from one value/level to the next value/level. In this "step elution" one or more conditions, for example the pH, the ionic strength, concentration of a salt, and/or the flow of a chromatography, is/are changed all at once from a first, e.g. starting, value to a 20 second, e.g. final, value, i.e. the conditions are changed incrementally, i.e. stepwise, in contrast to a linear change. In the "step elution method" is after each increase in the ionic strength a new fraction collected. This fraction contains the compounds recovered from the ion exchange material with the corresponding increase in ionic strength. After each increase the conditions are maintained till the next step in the 25 elution method. The terms "continuous elution" and "continuous elution method", which are used interchangeably within this application, denote a method wherein e.g. the concentration of a substance causing elution, i.e. the dissolution of a bound compound from a material, is raised or lowered continuously, i.e. the concentration 30 is changed by a sequence of small steps each not bigger than a change of 2 %, preferably of 1% of the concentration of the substance causing elution. In this "continuous elution" one or more conditions, for example the pH, the ionic strength, concentration of a salt, and/or the flow of a chromatography, may be changed linearly or exponentially or asymptotically. Preferably the change is linear.
-6 The term "applying to" and grammatical equivalents thereof as used within this application denotes a partial step of a purification method in which a solution, e.g. containing a substance of interest to be purified, is brought in contact with a stationary phase. This denotes that a) the solution is added to a chromatographic 5 device in which the stationary phase is located, or b) that a stationary phase is added to the solution. In case a) the solution, e.g. containing the substance of interest to be purified, passes through the stationary phase allowing for an interaction between the stationary phase and the substances in solution. Depending on the conditions, such as e.g. pH, conductivity, salt concentration, temperature, 10 and/or flow rate, some substances of the solution are bound to the stationary phase and, thus, are removed from the solution. Other substances remain in solution or are desorbed from the stationary phase. The substances in solution can be found in the flow-through. The "flow-through" denotes the solution obtained after the passage of the chromatographic device, which may either be the applied solution 15 containing the substance of interest or the buffer, which is used to flush the column or to cause elution of one or more substances bound to the stationary phase. In one embodiment the chromatographic device is a column, or a cassette. The substance of interest can be recovered from the solution after the purification step by methods familiar to a person of skill in the art, such as e.g. precipitation, salting out, 20 ultrafiltration, diafiltration, lyophilization, affinity chromatography, or solvent volume reduction to obtain the substance of interest in substantially homogeneous form. In case b) the stationary phase is added, e.g. as a solid, to the solution, e.g. containing the substance of interest to be purified, allowing for an interaction between the stationary phase and the substances in solution. After the interaction 25 the stationary phase is removed, e.g. by filtration, whereby e.g. the substance of interest is either bound to the stationary phase and removed therewith from the solution or not bound to the stationary phase and remains in the solution. The term "under conditions suitable for binding" and grammatical equivalents thereof as used within this application denotes that a substance of interest, e.g. 30 PEGylated erythropoietin, binds to a stationary phase when brought in contact with it, e.g. an ion exchange material. This does not necessarily denote that 100 % of the substance of interest is bound but essentially 100 % of the substance of interest is bound, i.e. at least 50 % of the substance of interest is bound, preferably at least 75 % of the substance of interest is bound, preferably at least 85 % of the substance 35 of interest is bound, more preferably more than 95 % of the substance of interest is bound to the stationary phase.
-7 The term "buffered" as used within this application denotes a solution in which changes of pH due to the addition or release of acidic or basic substances is leveled by a buffer substance. Any buffer substance resulting in such an effect can be used. In one embodiment pharmaceutically acceptable buffer substances are used, such as 5 e.g. phosphoric acid or salts thereof, acetic acid or salts thereof, citric acid or salts thereof, morpholine, 2-(N-morpholino) ethanesulfonic acid or salts thereof, histidine or salts thereof, glycine or salts thereof, or tris (hydroxymethyl) aminomethane (TRIS) or salts thereof. In a preferred embodiment phosphoric acid or salts thereof, or acetic acid or salts thereof, or citric acid or salts thereof, or 10 histidine or salts thereof are used. Optionally the buffered solution may comprise an additional salt, such as e.g. sodium chloride, sodium sulphate, potassium chloride, potassium sulfate, sodium citrate, or potassium citrate. General chromatographic methods and their use are known to a person skilled in the art. See for example, Chromatography, 5 'h edition, Part A: Fundamentals and 15 Techniques, Heftmann (ed) Elsevier Science Publishing Company 1992 Chromatography 5 1h ed 51 A 1992; Advanced Chromatographic and Electromigration Methods in Biosciences, Deyl, Z. (ed.), Elsevier Science BV, Amsterdam, The Netherlands, (1998); Chromatography Today, Poole, C. F., and Poole, S. K., Elsevier Science Publishing Company, New York, (1991); Scopes, 20 Protein Purification: Principles and Practice (1982); Sambrook, J., et al. (ed), Molecular Cloning: A Laboratory Manual , Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; or Current Protocols in Molecular Biology, Ausubel, F. M., et al. (eds), John Wiley & Sons, Inc., New York. 25 The PEGylation of erythropoietin normally results in a mixture of different compounds, such as poly-PEGylated erythropoietin, mono-PEGylated erythropoietin, not-PEGylated erythropoietin, hydrolysis products of the activated PEG ester, as well as hydrolysis products of the erythropoietin itself. In order to obtain a mono-PEGylated erythropoietin in substantially homogeneous form these 30 substances have to be separated and the compound of interest has to be purified. Therefore, it is the second aspect of the current invention to provide a method for obtaining a mono-PEGylated erythropoietin in substantially homogenous form comprising the following steps: a) PEGylating erythropoietin using an activated PEGylating reagent of a 35 molecular weight of from 20 kDa to 40 kDa, b) purifying the PEGylated erythropoietin obtained in step a) with two consecutive cation exchange chromatography steps, wherein the first and second cation exchange chromatography steps employ the same type of cation exchange material, 5 c) recovering the mono-PEGylated erythropoietin from the second cation exchange chromatography column in a substantially homogeneous form, d) regenerating the cation exchange chromatography column by a method according to the invention. 10 This method is especially useful for the purification of PEGylated recombinant polypeptides, which are glycosylated, i.e. which have been produced by a mammalian cell, preferably a CHO cell, HEK293 cell, BHK cell, Per.C66 cell, or HeLa cell and are afterwards chemically PEGylated. In one embodiment the regeneration of a cation exchange chromatography column comprises the following 15 steps: - removing bound polypeptides from the cation exchange column with an aqueous buffered solution comprising sodium chloride, - flushing the column with purified water, preferably with at least two column volumes, 20 - applying a sodium hydroxide solution to the column, preferably at least two column volumes, - flushing the column with purified water, preferably with at least two column volumes, - applying a solution comprising sodium dihydrogen phosphate and 25 phosphoric acid to the column, preferably at least three column volumes, - flushing the column with purified water, preferably with at least two column volumes, - applying a 0.5 M sodium hydroxide solution to the column for at least 4 hours, preferably for 4 hours, and -9 - regenerating the cation exchange column by flushing the column with purified water, preferably with at least two column volumes. In the first step of the method is the erythropoietin PEGylated. The poly (ethylene glycol) (PEG) polymer molecules used in the PEGylation reaction have a molecular 5 weight of about 20 kDa to 40 kDa (by "molecular weight" as used here there is to be understood the mean molecular weight of the PEG because PEG as polymeric compound is not obtained with a defined molecular weight but in fact has a molecular weight distribution; the term "about" indicates that in said PEG preparations, some molecules will weigh More and some less than the indicated 10 molecular weight, i.e the term about refers to a molecular weight distribution in which 95 % of the PEG molecules have a molecular weight within +/- 10 % of the indicated molecular weight. For example, a molecular weight of 30 kDa denotes a range of from 27 kDa to 33 kDa). The term "erythropoietin" refers to a protein having the sequence SEQ ID NO: 1 or 15 SEQ ID NO: 2, or a protein or polypeptide substantially homologous thereto, whose biological properties relate to the stimulation of red blood cell production and the stimulation of the division and differentiation of committed erythroid progenitors in the bone marrow. Recombinant erythropoietin may be prepared via expression in eukaryotic cells, for example in CHO cells, or BHK cells, or HeLa cells 20 by recombinant DNA technology or by endogenous gene activation, i.e. the erythropoietin glycoprotein is expressed by endogenous gene activation, see for example US 5,733,761, US 5,641,670, US 5,733,746, WO 93/09222, WO 94/12650, WO 95/31560, WO 90/11354, WO 91/06667, and WO 91/09955. In one embodiment the erythropoietin according to the invention is based on the sequence 25 of human EPO. In a preferred embodiment the human erythropoietin has the amino acid sequence set out in SEQ ID NO: I or SEQ ID NO: 2, more preferably the human erythropoietin has the amino acid sequence set out in SEQ ID NO: 1. The term "erythropoietin" also denotes variants of the protein of SEQ ID NO: 1 or SEQ ID NO: 2, in which one ore more amino acid residues have been changed, 30 deleted, or inserted, and which has the same biological activity as the not modified protein, such as e.g. reported in EP 1 064 951, or US 6,583,272. A variant may have the amino acid sequence of human erythropoietin having from I to 6 additional sites for glycosylation. The specific activity of PEGylated erythropoietin can be determined by various assays known in the art. The biological activity of the 35 purified PEGylated erythropoietin of this invention are such that administration of - 10 the protein by injection to human patients results in bone marrow cells increasing production of reticulocytes and red blood cells compared to non-injected or control groups of subjects. The biological activity of the PEGylated erythropoietin obtained and purified in accordance with this invention can be tested by methods 5 according to Pharmeuropa Spec. Issue Biologicals BRP Erythropoietin Bio 97-2 (1997) 31-48. "PEG" or "PEG group" according to the invention means a residue containing poly (ethylene glycol) as an essential part. Such a PEG can contain further chemical groups, which are necessary for binding reactions, which results from the chemical 10 synthesis of the molecule, or which are spacer for optimal distance of parts of the molecule. These further chemical groups are not used for the calculation of the molecular weight of the PEG polymer molecule. In addition, such a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs. Branched PEGs can 15 be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol. Branched PEG are described in, for example, EP 0 473 084, US 5,932,'462. As PEG with a molecular weight of 20-35 kDa linear PEG molecules are used in one embodiment and as PEG polymers with a molecular weight of more than 35 kDa, especially with 40 kDa, branched PEGs are 20 used in another embodiment. As PEG 40 kDa a two-armed PEG is particularly preferred. The term "PEGylation" means a covalent linkage of a poly (ethylene glycol) residue at the N-terminus of the polypeptide and/or an internal lysine residue. PEGylation of proteins is widely known in the state of the art and reviewed by, for example, 25 Veronese, F.M., Biomaterials 22 (2001) 405-417. PEG can be linked using different functional groups and poly (ethylene glycol)s with different molecular weight, linear and branched PEGs as well as different linking groups (see also Francis, G.E., et al., Int. J. Hematol. 68 (1998) 1-18; Delgado, C., et al., Crit. Rev. Ther. Drug Carrier Systems 9 (1992) 249-304). PEGylation of erythropoietin can be performed 30 in aqueous solution with PEGylation reagents as described, for example, in WO 00/44785, in one embodiment using NHS-activated linear or branched PEG molecules of a molecular weight between 5 kDa and 40 kDa. PEGylation can also be performed at the solid phase according to Lu, Y., et al., Reactive Polymers 22 (1994) 221-229. Not randomly, N-terminally PEGylated polypeptide can also be produced 35 according to WO 94/01451.
- 11 Such methods result in an erythropoietin which is PEGylated at one or more E amino groups of lysine residues and/or at the N-terminal amino group. Selective PEGylation at the N-terminal amino acid can be performed according to Felix, A.M., et al., ACS Symp. Ser. 680 (Poly(ethylene glycol)) (1997) 218-238. Selective 5 N-terminal PEGylation can be achieved during solid-phase synthesis by coupling of a N"-PEGylated amino acid derivative to the N-I terminal amino acid of the peptide chain. Side chain PEGylation can be performed during solid-phase synthesis by coupling of N'-PEGylated lysine derivatives to the growing chain. Combined N-terminal and side chain PEGylation is feasible either as described 10 above within solid-phase synthesis or by solution phase synthesis by applying activated PEG reagents to an amino deprotected peptide. Suitable PEG derivatives are activated PEG molecules with in one embodiment an average molecular weight of from about 5 to about 40 kDa, in a preferred embodiment of from about 20 to about 40 kDa, and in a more preferred 15 embodiment of about 30 kDa to about 35 kDa. The PEG derivatives can be linear or branched PEGs. A wide variety of PEG derivatives suitable for use in the preparation of PEG-protein and PEG-peptide conjugates can be obtained from Shearwater Polymers (Huntsville, AL, U.S.A.; www.nektar.com). Activated PEG derivatives are known in the art and are described in, for example, 20 Morpurgo, M., et al., J. Bioconjug. Chem. 7 (1996) 363-368, for PEG-vinylsulfone. Linear chain and branched chain PEG species are suitable for the preparation of the PEGylated fragments. Examples of reactive PEG reagents are iodo-acetyl-methoxy PEG, or methoxy-PEG-vinylsulfone (m is in one embodiment an integer from about 450 to about 900 and R is lower alkyl, linear or branched, having one to six 25 carbon atoms such as methyl, ethyl, isopropyl, etc. whereby methyl is preferred): 0 I O Oj\ 0 0 The use of these iodo-activated substances is known in the art and described e.g. by Hermanson, G. T., in Bioconjugate Techniques, Academic Press, San Diego (1996) p. 147-148.
- 12 In one embodiment the PEG species is an activated PEG ester, e.g., N-hydroxysuccinimidyl propionate, or N-hydroxysuccinimidyl butanoate, or N-hydroxysuccinimides such as PEG-NHS (Monfardini, C., et al., Bioconjugate Chem. 6 (1995) 62-69). In one embodiment the PEG is activated by N 5 hydroxysuccinimide ester 0 0 N O OR or 40 0 0 OH m 10 using alkoxy-PEG-N -hydroxysuccinimide, such as methoxy-PEG-N hydroxysuccinimide (MW 30000; Shearwater Polymers, Inc.), wherein R and m are as defined above. In one embodiment the PEG species is the N-hydroxysuccinimidyl ester of methoxy poly (ethylene glycol)-butyric acid. The 15 term "alkoxy" refers to an alkyl ether group in which the term 'alkyl' means a straight-chain or branched-chain alkyl group containing a maximum of four carbon atoms, such as methoxy, ethoxy, n-propoxy and the like, preferably methoxy. The term "substantially homogeneous form" as used within this application denotes 20 that the PEGylated erythropoietin obtained, contained, or used are those having a defined number of PEG group attached. In one embodiment the PEGylated erythropoietin is a mono-PEGylated erythropoietin. The preparation may contain unreacted (i.e., PEG group lacking) erythropoietin, poly-PEGylated erythropoietin, as well as fragments of the polypeptide generated during the PEGylation reaction. 25 The term "substantially homogeneous form" denotes that a preparation of a mono PEGylated erythropoietin contains at lest 50 % (w/w) of the mono-PEGylated erythropoietin, at least 75 % of the mono-PEGylated erythropoietin, at least 90 % of the mono-PEGylated erythropoietin, or more than 95 % of the mono-PEGylated erythropoietin. The percent values are based on the area-% of the chromatogram 30 corresponding to the cation exchange chromatography from which the mono PEGylated erythropoietin is obtained.
- 13 The current invention reports a method for the purification of a mono-PEGylated erythropoietin in order to obtain a substantially homogeneous form of a mono PEGylated erythropoietin. It has surprisingly been found that the combination of two consecutive cation exchange chromatography steps both employing the same 5 type of cation exchange material provides a substantially homogeneous form of a mono-PEGylated erythropoietin. Therefore the current invention provides a method for the purification of a mono-PEGylated erythropoietin comprising the steps of providing a solution comprising mono-, poly-, and not-PEGylated erythropoietin, performing two consecutive cation exchange chromatography steps, 10 recovering the purified mono-PEGylated erythropoietin in the second cation exchange chromatography step, wherein the same type of cation exchange material is used in both cation exchange chromatography steps, and regenerating the cation exchange chromatography column by a method according to the first aspect of the current invention. 15 The recovering of the purified mono-PEGylated erythropoietin in the second cation exchange chromatography step is by eluting the mono-PEGylated erythropoietin from the second cation exchange chromatography material. In one embodiment of the method according to the invention differ the two cation exchange chromatography steps in the elution method employed. The first cation exchange 20 chromatography step is in one embodiment performed as a step elution method, i.e. the ionic strength of the used buffer is increased stepwise, i.e. at once, from one ionic strength value to the next ionic strength value. The step elution method is in one embodiment performed as a three step elution method. In the first step mainly poly-PEGylated erythropoietin is eluted from the cation exchange chromatography 25 column. The second increase in ionic strength basically elutes the mono-PEGylated erythropoietin with a purity of more than 60 % based on the area of the corresponding size-exclusion chromatogram (area-%). The third increase in ionic strength elutes mainly the remaining not-PEGylated erythropoietin from the column. 30 The second cation exchange chromatography step is performed in one embodiment as a continuous elution method, i.e. the ionic strength of the buffer is increased continuously. The eluted fractions containing the mono-PEGylated erythropoietin are combined in order to obtain a mono-PEGylated erythropoietin in substantially homogeneous form, containing in one embodiment less than 0.5 % of low 35 molecular weight forms based on the area of the corresponding chromatogram. The - 14 buffer is in one embodiment present in a concentration of from 10 mM to 250 mM, preferably of from 50 mM to 150 mM, more preferably at about 100 mM. Therefore, in the method according to the invention are the two consecutive cation exchange chromatography steps the following steps: 5 a) applying an aqueous, buffered solution comprising a mixture of mono-, poly-, and not-PEGylated erythropoietin to a first cation exchange chromatography column under conditions suitable for binding of said mono-PEGylated erythropoietin to the cation exchange material contained in said first column, 10 b) recovering a mono-PEGylated erythropoietin from the first cation exchange chromatography column by a step elution method with a stepwise increase of the ionic strength of the through flowing buffer, wherein the relative content of mono-PEGylated erythropoietin is increased compared to the applied mixture of step a), 15 c) applying the recovered mono-PEGylated erythropoietin from step b) to a second cation exchange chromatography column under conditions suitable for binding of said erythropoietin to the cation exchange material contained in said second column, whereby the cation exchange material contained in said second column is of the same type as the 20 cation exchange material in the first column, d) recovering the purified mono-PEGylated erythropoietin in a substantially homogeneous form from said second cation exchange chromatography column by a continuous elution method with a continuous increase of the ionic strength of the through flowing buffer. 25 The PEGylation of a polypeptide does normally not provide the PEGylation product in homogeneous form. It is furthermore obtained as a mixture of mono PEGylated, poly-PEGylated, and not-PEGylated product. Therefore the solution of the PEGylated erythropoietin applied in step a) of the method is a mixture of mono-, poly-, and not-PEGylated erythropoietin and low molecular weight forms 30 or fragments in an aqueous buffer. The relative content of the different substances is determined by size exclusion chromatography (SE-HPLC). The sum of the area of the correlated peaks, i.e. the area under the peaks, in the size exclusion chromatogram is the total area of the size-exclusion chromatogram. The fraction of - 15 a single peak is given as area-%, i.e. as relative area fraction of the total area of the chromatogram. General chromatographic methods, their use, and the related terms are known to a person skilled in the art. See for example, Chromatography, 5 1h edition, Part A: 5 Fundamentals and Techniques, Heftmann (ed.), Elsevier Science Publishing Company, Chromatography 5 'h ed., 51 A (1992) and other related textbooks. During the chromatography a buffer is flowing through the cation exchange chromatography column. This "through flowing buffer" is adjusted according to the requirements of the steps of the chromatography method. It transports the 10 substance of interest to (applying) and from (eluting) the chromatographic material. In the first cation exchange chromatography step is the mixture of mono PEGylated, poly-PEGylated, and not-PEGylated erythropoietin applied at a protein concentration of about 1 mg/ml to the first cation exchange chromatography 15 column in an aqueous solution buffered with about 100 mM potassium phosphate at about pH 3.0. The term "about" as used within the current application denotes a range of 10 % around the given value, i.e. ± 10 %. Prior to and after the application is the first column washed with the same buffer solution. For the first step in the step elution method is the buffer changed to a buffer with about 100 mM 20 potassium phosphate, about 90 mM sodium chloride at about pH 3.0. With this buffer hydrolyzed PEG reagent, i.e. the corresponding PEGylated carbonic acid, unreacted coupling reagent, and poly-PEGylated erythropoietin are eluted from the cation exchange chromatography column. For the second step in the three step elution method is the buffer changed to a buffer with about 100 mM potassium 25 phosphate, about 250 mM sodium chloride at about pH 3.0. In this step the mono PEGylated erythropoietin is recovered from the first cation exchange chromatography column. The collected through flowing buffer of this elution step is diluted approximately 1:5 to 1:8 with purified water. After the first cation exchange chromatography step the recovered mono-PEGylated erythropoietin is 30 free of free PEG. The collected through flowing buffer of the second step of the first cation exchange chromatography is containing the mono-PEGylated erythropoietin in an increased relative content, i.e the fraction by weight or by area-% (in the chromatogram of a size exclusion chromatography of the collected through flowing buffer of the 35 second step) of the mono-PEGylated erythropoietin has increased when compared - 16 to prior to the first cation exchange chromatography step. In one embodiment is the relative content of mono-PEGylated erythropoietin at least 60 area-%. In a preferred embodiment is the relative content of mono-PEGylated erythropoietin at least 80 area-%. 5 For further purification of the mono-PEGylated erythropoietin a second cation exchange chromatography step is performed. For the second cation exchange chromatography is the collected and diluted through flowing buffer of the second elution step adjusted to a potassium phosphate concentration of about 100 mM and to a pH of about pH 3.0 applied to a second cation exchange chromatography 10 column containing a cation exchange material of the same type as the first cation exchange chromatography column. In one embodiment the second cation exchange column and the cation exchange material contained therein are the same as in the first cation exchange chromatography step. The mono-PEGylated erythropoietin is recovered from the second cation exchange chromatography 15 column by applying a linear gradient starting with potassium phosphate buffer of a concentration of about 100 mM with about 50 mM sodium chloride at about pH 3.0 and ending with a potassium phosphate buffer of a concentration of about 100 mM with about 500 mM sodium chloride at about pH 3.0. The change in the sodium chloride concentration is linear over ten column volumes. The through 20 flowing buffer is fractioned and each fraction is diluted with I M dipotassium hydrogen phosphate to increase the pH value to about pH 6 to 8. After the second cation exchange chromatography step is the mono-PEGylated erythropoietin obtained in substantially homogeneous form, preferably with a purity of at least 95 % by area. 25 A person of skill in the art is familiar with the technology of ion exchange chromatography. In the recovery step of the polypeptide bound to the cation exchange material the ionic strength, i.e. the conductivity, of the buffer/solution passing through the ion exchange column is increased. This can be accomplished either by an increased buffer salt concentration or by the addition of other salts, so 30 called elution salts, to the buffer solution. Depending on the elution method is the buffer/salt concentration increased at once (step elution method) or continuously (continuous elution method) by the fractional addition of a concentrated buffer or elution salt solution. In one embodiment the elution salt is sodium citrate, sodium chloride, sodium sulphate, sodium phosphate, potassium chloride, potassium 35 sulfate, potassium phosphate, or other salts of citric acid or phosphoric acid, or any - 17 mixture of these components. In a preferred embodiment the elution salt is sodium citrate, sodium chloride, potassium chloride, or mixtures thereof. In one embodiment of the current method is the cation exchange material a strong cation exchange material, in a preferred embodiment Toyopearle SP 650 M, in 5 another preferred embodiment a sulfopropyl cation exchange material. The concentration of the salt, causing the elution, is in one embodiment in the range of from 5 mM to 500 mM, in a preferred embodiment of from 5 mM to 400 mM, and in an especially preferred embodiment of from 5 mM to 250 mM. In another embodiment of the invention is the salt causing the elution at the same time used as 10 buffer substance, for example citric acid or salts thereof or phosphoric acid or salts thereof. The mono-PEGylated erythropoietin may be used in pharmaceutical compositions suitable for injection with a pharmaceutically acceptable carrier or vehicle by methods known in the art. For example, appropriate compositions have been 15 described in WO 97/09996, WO 97/40850, WO 98/58660, and WO 99/07401. Among the preferred pharmaceutically acceptable carriers for formulating the products of the invention are human serum albumin, human plasma proteins, etc. The compounds of the present invention may be formulated in 10 mM sodium/potassium phosphate buffer at pH 7 containing a tonicity agent, e.g. 132 20 mM sodium chloride. Optionally the pharmaceutical composition may contain a preservative. The pharmaceutical composition may contain different amounts of mono-PEGylated erythropoietin, e.g. 10 - 1000 pg/ml, e.g. 50 pg or 400 pg. Administration of the erythropoietin glycoprotein products of the present invention results in red blood cell formation in humans. Therefore, administration 25 of the mono-PEGylated erythropoietin glycoprotein product replenishes this erythropoietin protein which is important in the production of red blood cells. The pharmaceutical compositions containing the mono-PEGylated erythropoietin glycoprotein products may be formulated at a strength effective for administration by various means to a human patient experiencing blood disorders characterized by 30 low or defective red blood cell production, either alone or as part condition or disease. The pharmaceutical compositions may be administered by injection such as by subcutaneous or intravenous injection. Average quantities of the mono PEGylated erythropoietin glycoprotein product may vary. The exact amount of conjugate is a matter of preference subject to such factors as the exact type of - 18 condition being treated, the condition of the patient being treated, as well as the other ingredients in the composition. For example, 0.01 to 10 pg per kg body weight, preferably 0.1 to 1 pg per kg body weight, may be administered. e.g. once weekly. 5 It has surprisingly been found that a cation exchange chromatography column can be regenerated with a method according to the invention without a considerable decline in the separation efficiency. It has been shown that with a regeneration method according to the invention a cation exchange chromatography column can be used for at least 40 separation cycles, in one embodiment for at least 50 10 separation cycles, in a further embodiment for at least 60 separation cycles without a considerable decline in the separation efficiency (see Figure 1) and yield (see Figure 2). The term "separation cycle" as used within this application denotes the sequence i) equilibration of the column, ii) application of the solution to be separated on the column, iii) washing the column, iv) recovering the adsorbed 15 compounds from the column, v) washing the column, vi) regenerating the column. It has also been found that with the regeneration method according to the invention not only a decline in the separation efficiency can be avoided but also a decline in the loading capacity can be prevented (see Figure 2). The term "separation efficiency" as used within this application denotes the ability 20 of a cation exchange chromatography column to separate the compounds of a solution. The term "without a considerable decline" as used within this application denotes that the cation exchange chromatography column provides the same, i.e. within in variation of +/- 5 %, in one embodiment within a variation of +/- 2.5 %, compound separation in consecutive chromatographies of a solution containing the 25 same compounds. The term "loading capacity" as used within this application denotes the amount of a compound of interest that is recovered from a cation exchange chromatography column. The following examples, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the 30 appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
- 19 Description of the Figures Figure 1 Purity of mono-PEGylated erythropoietin in the through flowing buffer pool of the first chromatography during cycle number validation of the regeneration process. 5 Figure 2 Yield of mono-PEGylated erythropoietin in the through flowing buffer pool of the first chromatography during cycle number validation of the regeneration process. Materials and Methods SE-HPLC 10 SE-HPLC separates proteins according to their apparent molecular weight. Therefore, the method is able to detect the presence of mono-PEGylated erythropoietin, low molecular weight forms and fragments, poly-PEGylated forms and higher aggregates of erythropoietin. The HPLC is equipped with a 220-nm 15 detector and a Superose 6 HR column (dimensions 10 x 300 mm, Pharmacia Biotech, Cat-Nr: 17-0537-01) or a Superose 6 10/300 GL column (Pharmacia Biotech, Cat-Nr: 17-5172-01). The column is operated under isocratic conditions at room temperature, using a flow rate of about 0.4 ml/min. The mobile phase buffer is a 50 mM sodium phosphate buffer with 300 mM sodium chloride at pH 6.8. 20 Dependent on the HPLC-system used, the method can be performed with a sample application volume of either 100 pL or 500 pL. The samples are diluted with the mobile phase buffer to a protein concentration of about 0.5 mg/mL (100 pL load) or 0.1 mg/mL (500 pL load). Samples with a protein concentration of less than 0.1 mg/mL can be used undiluted. The eluted proteins are detected at a detector 25 wavelength of 220 nm. RP-HPLC: The purity is analyzed by RP-HPLC, which separates mono-PEGylated erythropoietin from oligo forms and related substances. The assay is performed on 30 a Poroshell column using an acetonitrile/aqueous TFA gradient. The elution profile is monitored as UV absorbance at 220 nm. The percentage of mono-PEGylated erythropoietin and related substances or oligo forms are calculated based upon the total peak area of the eluted proteins - 20 Example 1 Purification of mono-PEGylated erythropoietin Erythropoietin can be produced e.g. according to WO 01/87329, and purified as reported in WO 96/135718. PEGylated erythropoietin can be produced e.g. 5 according to WO 03/029291. a) First chromatography on SP Toyopearl 650 M The first chromatography step is performed on a sulfopropyl (SP) column packed with SP Toyopearl@ 650M. The column was operated at RT. The maximum loading capacity of the first column is defined as 1.5 g protein per liter column volume 10 (CV). The column was equilibrated with a 100 mM potassium phosphate buffer with pH 2.9 to 3.1 (SP-A buffer). After the loading step, the column was washed and eluted with a series of potassium phosphate buffers containing increasing amounts of NaCl. Free PEGylated carbonic acid, i.e. hydrolyzed PEG reagent, and poly-PEGylated forms were removed in the flow-through and the subsequent 15 washing step with SP-A buffer and 100 mM potassium phosphate buffer, pH 2.9 to 3.1, containing 90 mM sodium chloride (SP-B buffer), respectively. The mono-PEGylated erythropoietin was eluted by applying a 100 mM potassium phosphate buffer, pH 2.9 to 3.1, containing 250 mM sodium chloride (SP-C buffer), collected in a vessel and directly diluted 1:5 with purified water. This 20 collected eluate is termed ,,SP eluate pool I". The column was subsequently washed with 100 mM potassium phosphate buffer, pH 2.9 to 3.1, containing 750 mM sodium chloride (SP-D buffer) to remove unreacted erythropoietin and the column was regenerated. b) Second chromatography on SP Toyopearl 650 M 25 The second column was operated at RT. After equilibration with SP-A buffer the SP eluate pool I was applied to the column and the column was thereafter washed with SP-A buffer. The mono-PEGylated erythropoietin was eluted by applying a linear gradient with a slope of from 50 to 500 mM sodium chloride over ten column volumes buffered with 100 mM potassium phosphate buffer at 30 pH 2.9 to 3.1. The product peak was fractionated in up to 8 single fractions and each fraction was directly diluted with 1 M dipotassium hydrogen phosphate to increase the pH to 6 to 8. After the elution of mono-PEGylated erythropoietin was completed, the slope of the gradient can be increased leading to an immediate - 21 column wash with 100 mM potassium phosphate pH 2.9 to 3.1 containing 500 mM sodium chloride. c) Regeneration of the SP Toyopearl 650 M columns The resins of both columns were regenerated in a sequence of seven steps. The 5 columns were flushed with purified water followed by a 0.5 M sodium hydroxide solution. The alkaline solution was displaced with purified water followed by an acid wash (0.5 M sodium dihydrogen phosphate, I M phosphoric acid). After another purified water step, the columns were depyrogenated with 0.5 M sodium hydroxide for 4 hours. After caustic regeneration, the columns were washed with 10 purified water again. The purified water (PW III) was produced by ultrafiltration. The quality of PW III is equivalent to that of water for injection according to US Pharmacopeia. Testing is performed according to Ph. Eur. and USP. During control runs performed according to the above outlined first chromatography step no residual protein or PEG moieties could be detected in the respective through 15 flowing buffers. SDS-PAGE analysis of the resin after 60 cycles showed no residual protein or PEG moiety on the gel. Based on these data a batch-to-batch carryover of residual proteins and PEG moiety can be excluded and thus the regeneration of the column is very effective (see also Figure 1). The determination of the yield obtained in each chromatography showed no decline (see also Figure 2). 20 Table 1: Summary of parameters for the column regeneration. Column Parameters Step Buffer Solution Column Flow Rate Volumes [L/min] Rinse PW 1i1 22 1.6-2.1 Caustic 0.5 mol/L NaOH 2 1.6-2.1 column regeneration I Rinse PW 1i ?2 1.6-2.1 Acid column 1 mol/L phosphoric acid 2 3 1.6- 2.1 regeneration 0.5 mol/L sodium dihydrogen phosphate_______________ Rinse PW III 2 1.6-2.1 Caustic 0.5 mol/L NaOH 2 3 n. a. column regeneration 11 Rinse PW 111 22 1.6-2.1 As shown in Figures 1 and 2, the purity and yield of mono-PEGylated erythropoietin in the through flowing buffer pool for the first chromatography step - 22 for all cycles is clearly within the range of at least 80 % purity and at least 35 % yield. In addition, no trend in purity of mono-PEGylated erythropoietin during the lifetime of the column can be observed.
Claims (10)
1. Method for the regeneration of cation exchange chromatography column after the elution of compounds of interest comprising the following steps in this order: - eluting adsorbed polypeptides from the column with an aqueous buffered 5 solution comprising sodium chloride at a concentration of at least 500 mM, - flushing the column with purified water, - applying a 0.5 M sodium hydroxide solution to the column, - flushing the column with purified water, - applying a solution comprising 0.5 M sodium dihydrogen phosphate and 10 1 M phosphoric acid to the column, - flushing the column with purified water, - applying a 0.5 M sodium hydroxide solution to the column for at least 4 hours, and - regenerating the cation exchange chromatography column by flushing the 15 column with purified water.
2. Method for obtaining a mono-PEGylated erythropoietin in substantially homogenous form comprising the following steps: a) PEGylating erythropoietin using an activated PEGylating reagent of a molecular weight of from 20 kDa to 40 kDa, 20 b) purifying the PEGylated erythropoietin obtained in step a) with two consecutive cation exchange chromatography steps, wherein the first and second cation exchange chromatography steps employ the same type of cation exchange material, c) recovering the mono-PEGylated erythropoietin from the second cation 25 exchange chromatography column in a substantially homogeneous form, -24 d) regenerating the cation exchange chromatography column by the following steps in the following order: i) removing bound polypeptides from the cation exchange column with an aqueous buffered solution comprising sodium chloride, 5 ii) flushing the column with purified water, iii) applying a sodium hydroxide solution to the column, iv) flushing the column with purified water, v) applying a solution comprising sodium dihydrogen phosphate and phosphoric acid to the column, 10 vi) flushing the column with purified water, vii) applying a 0.5 M sodium hydroxide solution to the column for at least 4 hours, and viii) regenerating the cation exchange chromatography column by flushing the column with purified water. 15
3. Method according to claim I or 2, characterized in that said cation exchange chromatography column is a strong cation exchange chromatography column.
4. Method according to claim 3, characterized in that said cation exchange chromatography column is a sulfopropyl cation exchange chromatography column. 20
5. Method according to any one of the preceding claims, characterized in that said buffer is phosphoric acid or salts thereof, or acetic acid or salts thereof, or citric acid or salts thereof, or histidine or salts thereof.
6. Method according to claim 2, characterized in that said erythropoietin is human erythropoietin with an amino acid sequence of SEQ ID NO: I or 2. 25
7. Method according to any one of claims 2 or 6, characterized in that said PEG has a molecular weight of from 20-35 kDa and is linear. -25
8. Method according to any one of claims 2 or 6, characterized in that said PEG has a molecular weight of 40 kDa and is branched.
9. Method according to any one of claims 2 and 6 to 8, characterized in that said first cation exchange chromatography step is performed as a step elution and 5 said second cation exchange chromatography step is performed as a linear elution.
10. Method according to any one of the preceding claims, characterized in that said cation exchange chromatography column can be used at least for 40 separation cycles. 10 Dated 29 November 2012 F. Hoffmann-La Roche AG Patent Attorneys for the Applicant/Nominated Person SPRUSON & FERGUSON
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012258485A AU2012258485A1 (en) | 2007-07-17 | 2012-11-29 | Chromatographic methods |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07013960.5 | 2007-07-17 | ||
| AU2008277888A AU2008277888B2 (en) | 2007-07-17 | 2008-07-15 | Chromatographic methods |
| AU2012258485A AU2012258485A1 (en) | 2007-07-17 | 2012-11-29 | Chromatographic methods |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008277888A Division AU2008277888B2 (en) | 2007-07-17 | 2008-07-15 | Chromatographic methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2012258485A1 true AU2012258485A1 (en) | 2012-12-20 |
Family
ID=47360289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012258485A Withdrawn AU2012258485A1 (en) | 2007-07-17 | 2012-11-29 | Chromatographic methods |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2012258485A1 (en) |
-
2012
- 2012-11-29 AU AU2012258485A patent/AU2012258485A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008277888B2 (en) | Chromatographic methods | |
| AU2008277887B2 (en) | Purification of PEGylated peptides | |
| JP5735650B2 (en) | Method for purifying PEGylated erythropoietin | |
| AU2012258485A1 (en) | Chromatographic methods | |
| KR102470282B1 (en) | Method for purifying PEGized erythropoietin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK12 | Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal |